

**ASX Code: GSS**

28 October 2019

## **Genetic Signatures Limited completes \$35m placement**

- Genetic Signatures raises A\$35.0 million via a two-tranche placement at \$0.98 per share
- Substantial cornerstone investment from a large global fund manager and Australian institutional investors Perennial Value Management and Regal Funds Management
- Placement was supported by new and existing institutional investors
- Capital raising will accelerate the global rollout and rapidly drive revenue growth
- Funding should see the Company through to cash flow positive and profitability

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”), an emerging global leader in molecular diagnostics, is pleased to announce that it has successfully undertaken an institutional placement that will, on settlement, raise \$35 million through the issue of 35.7 million new ordinary shares (“**Placement**”).

The proceeds from the Placement will be used for commercial expansion in the European Union and USA, obtaining further regulatory approvals to Genetic Signatures’ products, additional product development including for new instrumentation, and working capital purposes.

The Placement was priced at \$0.98 per share, representing a 9.3% discount to the last closing price on Wednesday, 23 October 2019.

The Placement received overwhelming support from offshore investors and domestic institutional investors, including a large global fund manager, Perennial Value Management and Regal Funds Management.

**Genetic Signatures Chief Executive, John Melki, said:** “We are delighted with the significant broadening of our institutional register and the strong continued support from our existing shareholders, with demand for the placement exceeding the funds raised. Genetic Signatures is well funded to execute its commercial expansion strategy in Europe and the United States.”

“Global interest in our unique molecular diagnostic products continues to grow, driven by an increasing global awareness of the clinical and medical benefits and accuracy they deliver in the fight against infectious diseases. The funds raised will provide the resources to expedite our global expansion and take full advantage of growing demand worldwide from hospitals and laboratories,” he said.

The Placement is proposed to be settled in two tranches:

- The issue of the first tranche, consisting of 15.6 million new shares and raising ~\$15.3 million, is expected to occur on Monday, 4 November 2019 under Genetic Signatures’ existing placement capacity pursuant to ASX Listing Rule 7.1.

- The issue of the second tranche, consisting of 20.1 million new shares and raising \$19.7 million, is conditional on the Company obtaining shareholder approval. Genetic Signatures will be convening a meeting of shareholders in early December 2019 to seek this approval.

The shares to be issued under both tranches of the Placement are fully paid ordinary shares and will rank equally with existing shares in Genetic Signatures upon their issue.

Bell Potter Securities Limited acted as Lead Manager to the Capital Raising.

### Share Purchase Plan

In conjunction with the Placement, a share purchase plan will be made available to eligible shareholders (**SPP**). Under the SPP, holders of existing shares in Genetic Signatures on the share register as at 7.00pm (Sydney time) on Friday, 25 October 2019 and who are eligible shareholders in Australia or New Zealand will be invited to apply for up to \$30,000 of new fully paid ordinary shares in Genetic Signatures per eligible shareholder. The targeted raising size for the SPP is \$2 million.

Participation in the SPP will be optional. Further information in relation to the SPP, including the SPP issue price and other terms and conditions, will be outlined in a separate SPP Booklet which will be despatched to eligible shareholders and released on ASX on or around 4 November 2019.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

<b>John Melki</b> <b>Chief Executive Officer</b> <a href="mailto:john@geneticsignatures.com">john@geneticsignatures.com</a> T: +61 (0)2 9870 7580	<b>Peter Manley</b> <b>Chief Financial Officer</b> <a href="mailto:peter.manley@geneticsignatures.com">peter.manley@geneticsignatures.com</a>
--	---

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**<sup>™</sup>. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*<sup>™</sup> brand. Genetic Signatures' proprietary MDx **3base**<sup>™</sup> platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.